Principal Investigator - Prof Val Jenkins
Author - Prof Dame Lesley Fallowfield
Funder: ph Associates
EXPECT
Prostate cancer is the most common cancer for men in the UK. The main treatment for men with metastatic prostate cancer is hormonal therapy, which slows disease progression and alleviates symptoms. Unfortunately over time most patients will develop resistance to the hormone therapy and the cancer continues to grow. This is known as hormone refractory or castrate resistant prostate cancer (cRPC), which is initially treated with chemotherapy. In the EXPECT study (expectations and experiences of men with metastatic prostate cancer), we explored the type of information provided to patients and their partners by the health care professionals treating them regarding the benefits and side effects of further treatment. Certain side effects may have far more relevance to the decision-making process for some patients than clinicians are aware, for example what may be termed relatively minor symptoms by the clinician may in fact have a profound effect on certain individuals and strongly influence their decision-making process. In the EXPECT feasibility study we conducted a systematic review of the type of information required, decision making processes and Quality of Life (QoL) in men with cRPC and their partners.Current Stage:
Closed
Publication
Patient reported outcomes in metastatic castrate-resistant prostate cancer https://doi.org/10.1038/nrclinonc.2016.100Publication
No man's land: information needs and resources of men with metastatic castrate resistant prostate cancer https://doi.org/10.1007/s00520-016-3358-0Poster
Gaps and inconsistencies: Information for men with metastatic castrate resistant prostate cancer (mCRPC) posters/Final EXPECT 2.9.15.pdf Presented at European Cancer Congress 2015
EMAIL: adminshore-c@sussex.ac.uk
PHONE: 01273 873019
TWITTER: https://twitter.com/SussexSHORE_C
LOCATION: MAP